Thailand Medicinal Cannabis Card Service Logo

ROYAL GAZETTE DOCUMENTS

Page 60

Vol. 138
GOVERNMENT GAZETTE
14 May B.E. 2564
Special Issue 103 Ngor

Notification of the National Drug System Development Committee on the National Essential Medicines List, Herbal Aspect, B.E. 2564. Issued by virtue of ข้อ 8 (4) of the Prime Minister’s Office Regulation on the National Drug System Development Committee B.E. 2551. Signed 31 March B.E. 2564 by Anutin Charnvirakul, Deputy Prime Minister, Chairman of the Committee. Gazetted 14 May B.E. 2564, volume 138, special 103 ง, page 60. ข้อ 2: this Notification comes into force as from the day following the date of its publication in the Royal Gazette.

ข้อ 1 The herbal-drug items in the annexed list are drugs on the national essential medicines list, herbal aspect, for use in hospitals and public-health service units, with indications as approved by the authority under law, or a hospital formulary excepted by law, or a project approved by the herbal NLEM sub-committee. There are three sub-accounts.

Account 1 means drugs used to prevent and solve a health problem, with supporting evidence for the indication and sufficient experience of use in Thailand, usable in a medical facility, divided into 1.1 without a condition of use and 1.2 with a condition of use, such as the qualifications of the prescribing physician or the level of the facility.

Account 2 means drugs that must be used by a Thai traditional medicine practitioner, or a person assigned by the director of that facility, using Thai traditional medicine knowledge, with limited supporting evidence, and the facility must have a system to supervise, assess, and record use.

Account 3 means drugs for a special project of a State agency, with a responsible agency and budget, a written project, a defined period, a method of use, and follow-up, reported to the herbal NLEM sub-committee every six months and at the end of the project.

The annexed herbal-drug list includes: 1. ยาแก้ลมแก้เส้น (from คัมภีร์เวชศาสตร์วัณณา), powder, Account 2, for wind in the channels and muscle pain with numbness of the hands and feet. 2. Cannabis oil produced from inflorescence, having delta-9-tetrahydrocannabinol (THC) 2.0 mg/ml, oromucosal drops, Account 3. 3. Cannabis oil produced from root, stalk, branches, leaf, flower, and seed, oromucosal drops, Account 3. 4. Cannabis extract oil having cannabidiol (CBD) 100 mg/ml and delta-9-THC in a CBD:THC ratio greater than or equal to 20:1, oromucosal drops, Account 3. 5. Cannabis extract oil having delta-9-THC and CBD in a 1:1 ratio, oromucosal drops, Account 1 (1.2), as adjunct treatment in a late-stage cancer patient with insomnia, anorexia, or moderate to severe pain not treatable, or not successfully treated, with standard drugs, prescribed by a modern-medicine practitioner who has completed a medical-cannabis course the Ministry of Public Health recognises. 6. Cannabis extract oil having delta-9-THC not exceeding 0.5 mg/drop, oromucosal drops, Account 1 (1.2), as adjunct or combined treatment of chemotherapy-induced nausea and vomiting prescribed by a modern-medicine practitioner concerned with chemotherapy who has completed that course, and as adjunct treatment in late-stage cancer as for item 5. 7. ยาศุขไสยาศน์ (from คัมภีร์ธาตุพระนารายณ์), capsule or powder, Account 2.

This has not been officially translated. For the exact official text, please refer to the PDF. This is as accurate as possible from our team.

฿395Renewals ฿200Apply for your prescription